What are the diagnostic ultrasound findings for Placenta Accreta, Placenta Increta, and Placenta Percreta?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Ultrasound Findings for Placenta Accreta Spectrum

Ultrasound is the primary diagnostic modality for placenta accreta spectrum, with gray-scale and Doppler findings demonstrating 90.72% sensitivity and 96.94% specificity, though no single ultrasound feature reliably differentiates accreta from increta or percreta. 1

Key Clinical Context

The most important ultrasound association is placenta previa, present in >80% of placenta accreta spectrum cases, particularly in patients with prior cesarean delivery. 1

Gray-Scale Ultrasound Findings

Primary Diagnostic Features

  • Multiple vascular lacunae within the placenta represent the most specific finding, appearing as irregular sonolucent spaces with the highest positive predictive value for diagnosis 1, 2, 3

  • Loss of the normal hypoechoic retroplacental clear zone between placenta and myometrium, though this finding has lower specificity and generates more false positives, particularly in the third trimester 1, 2, 3

  • Decreased retroplacental myometrial thickness <1 mm indicates deep placental invasion 1, 2

  • Abnormalities of the uterine serosa-bladder interface, including interruption or irregularity of the hyperechoic interface between uterine serosa and bladder wall 1, 4

  • Extension of placenta into myometrium, serosa, or bladder suggests deeper invasion 1

Color Doppler Findings

Essential Vascular Markers

  • Turbulent lacunar blood flow is the most common and diagnostically useful Doppler finding for placenta accreta spectrum 1, 5, 2

  • Increased subplacental vascularity with hypervascularity at the placental bed 1, 2, 4

  • Gaps in myometrial blood flow indicating disruption of normal uterine vasculature 1

  • Vessels bridging the placenta to the uterine margin or bladder 1, 2

  • High-velocity flow >15 cm/s within placental lacunae 4

Advanced Imaging Findings

3D Power Doppler Features

  • Hypervascularity of the entire uterine serosa-bladder wall interface is specific for placenta percreta 4

  • Irregular intraplacental vascularization with tortuous confluent vessels affecting the entire placental width is specific for placenta percreta 4

Critical Limitations

No ultrasound feature or combination of features reliably predicts the depth of invasion or accurately differentiates between accreta, increta, and percreta. 1, 6 This is because adherent and invasive placentation may coexist in the same placental bed and evolve with advancing gestation 6.

Diagnostic Approach Algorithm

Optimal Scanning Technique

  • Use combined transvaginal and transabdominal ultrasound with high-frequency (5-9 MHz) linear probe when body habitus permits 2

  • Ensure bladder is moderately full (200-300 mL) to properly evaluate the lower uterine segment and cesarean scar area 2

  • Apply minimal probe pressure when assessing the retroplacental clear zone to avoid artifactual loss 2

  • Add color Doppler and power Doppler imaging to significantly improve detection sensitivity 2, 4

Timing of Evaluation

  • Screen at 18-22 weeks during second trimester anatomy scan in at-risk patients 2

  • Features may be visible as early as 15-20 weeks gestation, with 86% detection rate in confirmed cases 3

  • Serial evaluations are recommended as findings evolve with advancing gestation 6

Diagnostic Certainty Based on Number of Findings

  • 0 signs present: 5% likelihood of placenta accreta spectrum 7
  • 1 sign present: 24% likelihood 7
  • 2 signs present: 57% likelihood 7
  • ≥3 signs present: 94% likelihood 7

Important Pitfalls to Avoid

The obliteration of retroplacental clear space alone is not reliable for diagnosis due to high false-positive rates, especially in the third trimester 3. Multiple lacunae with turbulent flow provide much higher diagnostic certainty 1, 3.

Distinguish true placenta accreta spectrum lacunae from benign placental lakes by assessing for associated findings: PAS-associated lacunae occur with loss of retroplacental clear zone, thinned myometrium <1mm, placenta previa, and turbulent flow on Doppler 5.

Clinical risk factors (placenta previa with prior cesarean delivery) remain equally important as ultrasound findings, as absence of ultrasound findings does not preclude diagnosis 1.

Management Implications

Women with suspected placenta accreta spectrum should be referred to a level III or IV maternal care facility with multidisciplinary expertise for delivery planning 1, 5. Planned delivery at 34 0/7 to 35 6/7 weeks gestation optimizes outcomes in stable patients 1, 8.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Optimal Ultrasound Probe Selection for Ruling Out Placenta Accreta

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Morbidly adherent placenta: evaluation of ultrasound diagnostic criteria and differentiation of placenta accreta from percreta.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2013

Guideline

Placental Lakes and Their Clinical Significance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Evaluation of classic and novel ultrasound signs of placenta accreta spectrum.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2022

Guideline

Anesthetic Management for Placenta Percreta

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.